Molecular biology of leukemia

Seminars in Oncology Nursing

Volumn 19, Issue 2, 2003, Pages 83-89

  Wujcik, Debra ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; IMATINIB; RETINOIC ACID; TRISONEX; TUMOR MARKER;

ACUTE LEUKEMIA; ALGORITHM; BLOOD SAMPLING; BONE MARROW; BONE MARROW BIOPSY; CANCER DIAGNOSIS; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION; CHRONIC LEUKEMIA; CYTOGENETICS; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA; MOLECULAR BIOLOGY; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; REVIEW; ADULT; BONE MARROW CANCER; BONE MARROW EXAMINATION; CHROMOSOME ABERRATION; CLASSIFICATION; GENETICS; KARYOTYPING; METHODOLOGY; NURSE ATTITUDE; NURSING; ONCOLOGY NURSING; PATHOLOGY; STANDARD;

ADULT; BONE MARROW; BONE MARROW EXAMINATION; BONE MARROW NEOPLASMS; CHROMOSOME ABERRATIONS; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; KARYOTYPING; LEUKEMIA; NURSE'S ROLE; ONCOLOGIC NURSING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0038500693     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-2081(03)00004-4     Document Type: Article

References (46)

1. Thandla S., Aplan P.D. Molecular biology of acute leukemia. Semin Oncol. 24:1997;45-56
2. Caligiuri M.A., Strout M.P., Gilliland D.G. Molecular biology of acute myeloid leukemia. Semin Oncol. 24:1997;32-44
3. Strout M.P., Caligiuri M.A. Developments in cytogenetics and oncogenes in acute leukemia. Curr Opin Oncol. 9:1997;8-17
4. Mrozek K., Heinomen K., Bloomfield C.D. Prognostic value of cytogenetic findings in adults with acute myeloid leukemia. Int J Hematol. 72:2000;261-271
5. Dohner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 343:2000;1916-1920
6. Faderl S., Kantarjian H.J., Talpaz M., et al. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood. 91:1998;3995-4019
7. Mrozek K., Heinonen K., de la Chapelle A. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol. 24:1997;17-31
8. Hayashi Y. The molecular genetics of recurring chromosome abnormalities in acute myeloid leukemia. Semin Hematol. 37:2000;360-380
9. Stone R.M. Postremission therapy in adults with acute myeloid leukemia. Semin Hematol. 38:2001;17-23
10. Kelly L., Clark J., Gilliland D.G. Comprehensive genotypic analysis of leukemia Clinical and therapeutic implications. Curr Opin Oncol. 14:2002;10-18
11. National Cancer Institute Cancer Genome Anatomy Project. Available at http://cgap.nci.nih.gov/Genes (accessed March 26, 2003)
12. Hiddemann W., Buchner T. Current status and perspectives of therapy for acute myeloid leukemia. Semin Hematol. 38:2001;3-9
13. Miller K.B., Grodman H.M. Leukemia. Lenhard R.E., Osteen R.T., Gansler T. Clinical Oncology. 2001;527-551 American Cancer Society, Atlanta, GA
14. Scheinberg D.A., Maslak P., Weiss P. Acute leukemias. DeVita V.T., Hellman S., Rosenberg S.A. Cancer: Principles and Practices of Oncology. 2001;2404-2433 Lippincott, Williams & Wilkins, Philadelphia, PA
15. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the acute leukemias. Br J Haematol. 33:1976;451-458
16. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med. 102:1985;626-629
17. Riley R.S., Massey D., Jackson-Cook C., et al. Immunophenotypic analysis of acute lymphocytic leukemia. Hematol Oncol Clin North Am. 16:2002;245-299
18. Harris N.L., Jaffe E.S., Diebold J., et al. World Health Organization classification of neoplastic disease of the hematopoietic and lymphoid tissues Report of the clinical advisory committee meeting-Airlie House, VA, November 1997. J Clin Oncol. 17:1999;3835-3849
19. Head D.R. Proposed changes in the definitions of acute myeloid leukemia and myelodysplastic syndromes Are they helpful? Curr Opin Oncol. 14:2002;19-23
20. Faderl S., Talpaz M., Estrov Z., et al. The biology of chronic myeloid leukemia. N Engl J Med. 341:1999;164-172
21. Deininger M.W., Goldman J.M., Melo J.V. The molecular biology of chronic myeloid leukemia. Blood. 96:2000;3343-3356
22. Zweibel J.A., Cheson B.D. Chronic lymphocytic leukemia Staging and prognostic factors. Semin Oncol. 25:1998;42-59
23. Bloomfield C.D., Caligiuri M.A. Molecular biology of leukemias. DeVita V.T., Hellman S., Rosenberg S.A. Cancer: Principles and Practices of Oncology. 2001;2389-2404 Lippincott, Williams & Wilkins, Philadelphia, PA
24. Trewhitt K.G. Bone marrow aspiration and biopsy Collection and interpretation. Oncol Nurs Forum. 28:2001;1409-1417
25. Pfeifer J.D., Wick M.R. Pathologic evaluation of neoplastic disease. Lenhard R.E., Osteen R.T., Gansler T. Clinical Oncology. 2001;123-147 American Cancer Society, Atlanta, GA
26. Jain N.C., Cox C., Bennett J.M. Auer rods in the acute myeloid leukemias Frequency and methods of demonstration. Hematol Oncol. 5:1987;197-202
27. Rowley J.D. Cytogenetic analysis in leukemia and lymphoma An introduction. Semin Hematol. 37:2000;315-319
28. Stolzfus P.K., Rust D., Ried T. Molecular cytogenetics and gene analysis Implications for oncology nurses. Clin J Oncol Nurs. 5:2001;201-206
29. Braylon R.C., Orfao A., Borowitz M.F., et al. Optimal number of reagents required to evaluate hematolymphoid neoplasias Results of an international consensus meeting. Cytometry. 46:2001;23-27
30. Abrahamsen J.F., Lund-Johansen F., Laerum O.D., et al. Flow cytometric assessment of peripheral blood contamination and proliferative activity of human bone marrow population. Cytometry. 19:1995;77-85
31. McCoy P.J. Basic principles of flow cytometry. Hematol Oncol Clin North Am. 16:2002;229-243
32. Marti G.E., Stetler-Stevenson M., Bleesing J., et al. Introduction to flow cytometry. Semin Hematol. 38:2001;93-99
33. Weir E.G., Borowitz M.J. Flow cytometry in the diagnosis of acute leukemia. Semin Hematol. 38:2001;124-138
34. Todd W.M. Acute myeloid leukemia and related conditions. Hematol Oncol Clin North Am. 16:2002;301-319
35. Ferrando A.A., Look A.T. Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia. Semin Hematol. 37:2000;381-395
36. Hokland P., Pallisgaard N. Integration of molecular methods for detection of balanced translocations in the diagnosis and follow-up of patients with leukemia. Semin Hematol. 37:2000;358-367
37. Bloomfield C.D., Lawrence D., Byrd J.C., et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 58:1998;4173-4179
38. Kern W., Schoch C., Haferlach T. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy Relevance of cytogenetic abnormalities. Leukemia. 14:2000;226-231
39. Grimwade D., Walker H., Oler F., et al. The importance of diagnostic cytgenetics on outcome in AML Analysis of 1, 612 patients entered in the MRC AML 10 trial. Blood. 92:1998;2322-2333
40. Lowenberg B. Managing therapy in older adult patients with acute myeloid leukemia. Semin Hematol. 38:2001;10-16
41. Buchner T., Hiddemann W., Berdel W., et al. Acute myeloid leukemia Treatment over 60. Rev Clin Exp Hematol. 6:2002;46-59
42. Slack J.L., Rusiniak M.E. Current issues in the management of acute promyelocytic leukemia. Ann Hematol. 79:2000;227-238
43. Davison K., Mann K., Miller W. Arsenic trioxide Mechanism of action. Semin Hematol. 39:(suppl 1):2002;3-7
44. Dombret H., Fenaux P., Soignet S., et al. Established practice in the treatment of patients with acute promyelocytic leukemia and the introduction of arsenic trioxide as a novel therapy. Semin Hematol. 39:2002;8-13
45. Kantarjian M.D., Sawyers C.L., Hochhaus A., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 346:2002;645-652
46. Savage D.G., Antman K.H. Imatinib mesylate A new oral targeted therapy. N Engl J Med. 346:2002;683-692